Karo Bio receives patent on estrogen receptor complex

KARO BIO RECEIVES PATENT ON ESTROGEN RECEPTOR COMPLEX

Karo Bio today announced that the Company has received patent protection
for three-dimensional structures of the estrogen receptor beta.

Estrogen acts by binding to its receptor in cells of target tissues. The
receptor is a protein with hundreds of amino acids and contains
thousands of atoms with a specific three-dimensional arrangement (3D).
Female sex hormones and pharmaceutical compounds function by affecting
the 3D structure of the receptor. Knowledge about the 3D structure is
therefore of great importance for design of new pharmaceutical
compounds.

Karo Bio has now received US patent protection for several 3D structures
in complex with different chemical compounds. This is significant since
there are two separate receptors for estrogen, the female sex hormone.
The two receptors perform different functions and development of
receptor selective compounds may lead to new treatments in the field of
women’s health care

Karo Bio has previously received patent protection for use of the gene
encoding ER beta and has filed several patents covering new clinical
indications, chemical compounds and receptor structure related
information. The new issued patent is therefore an important piece in a
broad and long-term patent strategy.

KARO BIO AB (publ)

For further information contact:
Karo Bio AB
Per Otteskog, Acting President, Karo Bio
Direct telephone: +46-8-608 6018
Mobile telephone: +46-70-632 7527

Background

Karo Bio is a company with operations in the United States and Sweden.
The Company employs 120 people and has 250 patent cases including 100
approved patents.

Karo Bio has been listed on the Stockholm stock exchange (KARO) since
1998 and has a leading position in the field of drug discovery and
nuclear receptors. Nuclear receptors are important and validated drug
targets for a number of clinical indications and the Company uses
proprietary technologies for the development of novel and improved
therapies for major markets. An important base for generation of new
therapeutic strategies is Karo Bio’s strong academic network.

Karo Bio has drug discovery programs in therapeutic areas such as
women’s health care, metabolic disorders, cardiovascular disease,
diabetes, dermatology, ophthalmology and infectious disease.

Karo Bio collaborates with major pharmaceutical companies for
development of products through clinical trials and marketing. In these
partnerships Karo Bio receives downpayments, R&D funding and royalties
on net sales when products reach the market.

Karo Bio’s product pipeline is strong and includes a number of
proprietary projects that will be partnered in different stages. Karo
Bio generally collaborates with major pharmaceutical companies from
early drug discovery through clinical trials but also takes the
opportunity to bring products to the clinic before partnering. Apart
from financial compensations the partners bring competence and resources
for drug development and marketing to the collaboration.

Karo Bio has one product in clinical trials and expects to enter
clinical trials with partners in the future.

Karo Bio has a strong financial position and it’s partnerships include
Abbott Laboratories, Bristol-Myers Squibb, Merck & Co., Aventis Pharma,
Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc. GPC Biotech,
NovImmune S.A., and Serono International S.A.

————————————————————
This information was brought to you by Waymaker https://www.waymaker.net
The following files are available for download:
https://www.bit.se/bitonline/2001/06/07/20010607BIT00040/bit0001.doc
https://www.bit.se/bitonline/2001/06/07/20010607BIT00040/bit0001.pdf